RBOT vs. BSGM, INGN, CVRX, AVR, LNSR, RPID, LUCD, ARAY, ATOS, and MGRM
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Biosig Technologies (BSGM), Inogen (INGN), CVRx (CVRX), Anteris Technologies Global (AVR), LENSAR (LNSR), Rapid Micro Biosystems (RPID), Lucid Diagnostics (LUCD), Accuray (ARAY), Atossa Genetics (ATOS), and Monogram Orthopaedics (MGRM). These companies are all part of the "med instruments" industry.
Vicarious Surgical vs. Its Competitors
Vicarious Surgical (NYSE:RBOT) and Biosig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Biosig Technologies has higher revenue and earnings than Vicarious Surgical.
Vicarious Surgical presently has a consensus target price of $9.25, suggesting a potential upside of 21.55%. Biosig Technologies has a consensus target price of $10.00, suggesting a potential downside of 2.30%. Given Vicarious Surgical's higher possible upside, equities research analysts plainly believe Vicarious Surgical is more favorable than Biosig Technologies.
Vicarious Surgical has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
Vicarious Surgical's return on equity of -120.53% beat Biosig Technologies' return on equity.
47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 12.0% of Vicarious Surgical shares are owned by insiders. Comparatively, 17.0% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Vicarious Surgical had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Vicarious Surgical and 2 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.61 beat Vicarious Surgical's score of 0.22 indicating that Biosig Technologies is being referred to more favorably in the news media.
Summary
Biosig Technologies beats Vicarious Surgical on 7 of the 12 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vicarious Surgical Competitors List
Related Companies and Tools
This page (NYSE:RBOT) was last updated on 7/5/2025 by MarketBeat.com Staff